Application of Biopharmaceuticals in the Treatment of Neurological Diseases

Neurological diseases, such as Alzheimers disease (AD) and Parkinsons disease (PD), have long posed significant health challenges due to their complex pathogenesis and the profound impact they have on patients' quality of life. Traditional treatments often fall short of providing radical cures, particularly hindered by barriers like the blood-brain barrier (BBB). In recent years, biopharmaceuticalsleveraging advanced technologies such as genetic engineering and cell engineeringhave emerged as promising therapeutic alternatives. This paper summarizes biopharmaceutical strategies for treating these two neurological diseases, analyzes the advantages and disadvantages of biopharmaceutical technologies in disease treatment, and provides a detailed description of the pathogenesis and clinical manifestations of these diseases. The conclusion highlights that biopharmaceutical technology has become one of the most effective means for treating neurological diseases, but it still faces obstacles and limitations. Future advancements require technological improvements and clinical trials to enhance treatment success rates and refine preventive measures for neurological diseases.